Mandate

Vinge has advised CELLINK in a directed issue of new shares

Vinge has advised CELLINK AB (publ) in connection with a directed issue of new shares which will generate approximately MSEK 377 for CELLINK.

The subscription price was determined through an accelerated book‑building and corresponds to a discount of 3.4 per cent compared with the volume‑weighted average listed price during January on Nasdaq First North Growth Market. In addition to considerable support from existing shareholders, several new Swedish and institutional shareholders subscribed for the new issue of shares. An amount of MSEK 150 from the proceeds in relation to the new issue of shares will be used to finance the company’s organic growth plan, future operating capital requirements, etc. and the remaining proceeds can be used to finance strategic acquisitions.

Vinge’s team consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025